

¹The Austrian Agency for Health and Food Safety, Vienna, Austria; ²The 2nd European *Clostridioides difficile* Infection Surveillance Network (ECDIS-Net-2) Consortium; ³ Disease Programme Unit, European Centre for Disease Prevention and Control (ECDC); Solna, Sweden; ⁴Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands;

Cross-sectional survey of *Clostridioides difficile* infection diagnostic and typing capacity in 31 European countries in 2018

Background

Suboptimal diagnostic testing for Clostridioides difficile infection (CDI) affects patient management, surveillance and prevention. In 2011 and 2014, ECDC ECDIS-Net surveys in 33 European countries recorded optimal diagnostic practices in 19% and 46% of laboratories, the participating respectively. In 2014, 16/32 (50.0%) countries had capillary-based (CE) PCR ribotyping capacity.

Aim of the study

This survey sought to describe European CDI diagnostic and typing capacity in 2018

Methods

In December 2018, ECDIS-Net-2 sent a web-based questionnaire on national CDI diagnostic practices, to national-level experts, designated by ECDC's National Focal Points for Healthcare-Associated Infections, in all 37 EU/EA countries. These experts forwarded another web-based questionnaire on local CDI diagnostic practices to local laboratories in their country. In countries with >20 responding laboratories, we randomly selected 20 responses. In total, 364 laboratories participated

No response: Liechtenstein, UK-Scotland, UK-Northern Ireland and the Republic of North Macedonia



Results

	EU/EA countries (n=37)	%
Changed/updated national CDI diagnostic guidelines since 2014	22/37	59%
Adopted the 2016 ESCMID diagnostic algorithm	18/23	78%
Introduced national CDI surveillance program	9/26	35%
Availability of national <i>C. difficile</i> typing laboratory	25/26	96%
Performance of CE-PCR ribotying	22/26	85%
Use of ECDC reference panel of PCR ribotypes	16/26	62%
Identifies need further training for CE-PCR ribotyping	9/37	24%
Performs <i>C. difficile</i> susceptibility testing	8/37	22%

	Microbiological labs (n= 364)	%
CDI testing only on physicians	169/307	55%
request		
CDI testing of all hospitalized	58/364	16%
patients with onset of diarrhea at		
least 48 h following admission		
Testing all diarrheal patients ≥ 65	32/364	9%
years of age		
Testing all diarrheal patients with	41/364	11%
recently completed course of		
antibiotics shorter than 1 month		
Use of ESCMID-recommended	197/364	54%
two-step algorithm to diagnose		
CDI		
Use of two steps with combined	116/197	59%
GDH and toxin test as first step		

Conclusion

Europe has further improved its capacity to diagnose CDI, measure prevalence and identify subtypes, thus permitting better targeting of local and national public health actions.





